Trial Profile
An open-label study to determine the maximum tolerated dose of Tarceva [erlotinib] in combination with Alimta [pemetrexed] in patients with advanced non-small cell lung cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Feb 2010
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Roche
- 09 Jan 2008 New trial record.